Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. Creative Biolabs provides a wide range of ADCC enhanced antibodies used in various research areas to accelerate your research process.
Antibody-dependent cell-mediated cytotoxicity (ADCC), also referred to as antibody-dependent cellular cytotoxicity, is a mechanism of cell-mediated immune defense. Antigens coated by specific antibodies are lysed by a cytotoxic effector cell through a non-phagocytic process. ADCC is triggered through interaction of an antibody’s Fc region with certain Fc receptors (FcRs) on effector cells (including natural killer (NK) cells, monocytes, macrophages, neutrophils, eosinophils and dendritic cells) and reached by the release of the content of cytotoxic granules or by the expression of cell death-inducing molecules. ADCC is highly dependent on the glycosylation profile of its Fc portion and on the polymorphism of Fcγ receptors.
Our Afuco™ ADCC enhanced antibodies, also known as afucosylated antibodies, are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units. When antibodies are afucosylated the effect is to increase ADCC. Normal CHO cell line are not suitable for the production of completely defucosylated antibodies as they retain a high level of intrinsic α-1,6-fucosyltransferase enzyme activity, which is responsible for the core fucosylation of N-linked Oligosaccharides. Non-fucosylated therapeutic antibodies are Afucosylated monoclonal antibodies with enhanced ADCC activity and they are manufactured by using our fucosyltransferse-engineered cell line.
Creative Biolabs is a trusted partner in antibody production. For more detail information, please do not hesitate to contact us.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.